not tagged
Not Tagged
[]
 first report on clinical utility of tumor-guided ctdna (minimal residual disease) in stage ii colon cancer (dynamic) potential to reduce chemotherapy use from 28% to 15% no differences in outcomes 
MD/MBA, Medical Director Oncoclínicas Precision Medicine, Oncology Data Scientist at VHIO Digital Health. Views my own. Advisory/speaker Roche and others.